Could a cystic fibrosis drug ease stubborn sinus infections?

NCT ID NCT03439865

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether ivacaftor, a drug used for cystic fibrosis, can help people with chronic sinusitis caused by hard-to-treat bacteria. Twenty adults will receive either ivacaftor plus standard care or standard care alone for 14 days. Researchers will check safety, symptom scores, and infection markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ivacaftor (Kalydeco)

What this could lead to

If it works, this could point toward a new treatment option for chronic sinus infections that don't respond to standard care.

What could go wrong

This is a very early, small pilot study with only 20 people. It may not show clear benefits, and ivacaftor is not yet proven for this condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic rhinosinusitis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••